Skip to content

Safety and efficacy of Siemens MAGNETOM Free.Star 0.55T magnetic resonance follow-up in patients with NF2 after auditory implantation (artificial auditory brainstem/cochlear implant)

Safety and efficacy of Siemens MAGNETOM Free.Star 0.55T magnetic resonance follow-up in patients with Neurofibromatosis type 2 (NF2) after auditory implantation (artificial auditory brainstem/cochlear implant)

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400085690
Enrollment
Unknown
Registered
2024-06-17
Start date
2024-01-15
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurofibromatosis type 2,NF2

Interventions

Trail group:NA

Sponsors

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) 18-75 years old (including 18 and 75 years old); (2) Patients with severe or above deafness due to neurofibromatosis type 2 and cochlear/auditory brain stem implantation; (3) Agree to participate in the trial and sign the informed consent;

Exclusion criteria

Exclusion criteria: (1) Intellectual disability; (2) mental illness; (3) Poor general condition, unable to accept MR Evaluators; (4) Allergic to magnetic resonance contrast agents; (5) Patients with metal devices including cardiac pacemakers, functional stimulators, heart stents, metal foreign bodies in the eyes, and metal clips after aneurysm surgery.

Design outcomes

Primary

MeasureTime frame
The degree of clarity shown to the surrounding and contralateral anatomy of the implant;Signal to noise ratio;comfort level and pain degree when scanning ;

Secondary

MeasureTime frame
Metal artifact;

Countries

CHINA

Contacts

Public ContactChai Yongchuan

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

cycperfect@163.com+86 138 1676 3040

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026